U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C29H30O8.C2H8N2
Molecular Weight 1073.1857
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ENRASENTAN EDAMINE

SMILES

NCCN.CCCOC1=CC=C2[C@@H]([C@H]([C@@H](C2=C1)C3=CC=C(OC)C=C3OCCO)C(O)=O)C4=CC5=C(OCO5)C=C4.CCCOC6=CC=C7[C@@H]([C@H]([C@@H](C7=C6)C8=CC=C(OC)C=C8OCCO)C(O)=O)C9=CC%10=C(OCO%10)C=C9

InChI

InChIKey=WWCIKXJATPIKHK-HTFWYUNBSA-N
InChI=1S/2C29H30O8.C2H8N2/c2*1-3-11-34-19-6-7-20-22(14-19)27(21-8-5-18(33-2)15-24(21)35-12-10-30)28(29(31)32)26(20)17-4-9-23-25(13-17)37-16-36-23;3-1-2-4/h2*4-9,13-15,26-28,30H,3,10-12,16H2,1-2H3,(H,31,32);1-4H2/t2*26-,27+,28+;/m00./s1

HIDE SMILES / InChI

Molecular Formula C2H8N2
Molecular Weight 60.0983
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C29H30O8
Molecular Weight 506.5437
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800004637 | https://www.ncbi.nlm.nih.gov/pubmed/16339819

Enrasentan is an orally active mixed endothelin A/B receptor antagonist with a 100-fold greater affinity for the endothelin A receptor. In an animal model of hypertension and cardiac hypertrophy the drug has reduced blood pressure, prevented cardiac hypertrophy and preserved myocardial function. In rats with hyperinsulinemia and hypertension enrasentan normalized blood pressure and prevented cardiac and renal damage. In rats with stroke the drug reduced the ischemic area in the brain. Enrasentan had been in phase II clinical trial for the treatment of heart failure but the results suggested that enrasentan does not appear to have favorable effects on ventricular remodeling.

Approval Year

PubMed

PubMed

TitleDatePubMed
Endothelin receptor antagonists.
2006 Jun
Patents

Patents

Sample Use Guides

60-90 mg once daily
Route of Administration: Oral
The functional activity of enrasentan was evaluated in vitro in rat isolated aorta. In this model enrasentan (10 to 1000 nM) produced concentration-dependent, parallel rightward shifts in the ET-1 concentration-response curve. The Kb value for inhibition of ET-1-induced contraction for enrasentan was 4.4 ± 0.6 nM. The drug was devoid of agonistic activity. In human isolated pulmonary artery enrasentan produced a 7-fold shift to the right of the ET-1 concentration-response curve, with a calculated Kb value of 5.2 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:41:53 UTC 2023
Edited
by admin
on Fri Dec 15 15:41:53 UTC 2023
Record UNII
W4N3HUS9UW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ENRASENTAN EDAMINE
Common Name English
1H-INDENE-2-CARBOXYLIC ACID, 1-(1,3-BENZODIOXOL-5-YL)-2,3-DIHYDRO-3-(2-(2-HYDROXYETHOXY)-4-METHOXYPHENYL)-5-PROPOXY-, (1S-(1.ALPHA.,2.BETA.,3.ALPHA.))-, COMPD. WITH 1,2-ETHANEDIAMINE (2:1)
Common Name English
1H-INDENE-2-CARBOXYLIC ACID, 1-(1,3-BENZODIOXOL-5-YL)-2,3-DIHYDRO-3-(2-(2-HYDROXYETHOXY)-4-METHOXYPHENYL)-5-PROPOXY-, (1S,2R,3S)-, COMPD. WITH 1,2-ETHANEDIAMINE (2:1)
Common Name English
Code System Code Type Description
PUBCHEM
15886604
Created by admin on Fri Dec 15 15:41:53 UTC 2023 , Edited by admin on Fri Dec 15 15:41:53 UTC 2023
PRIMARY
FDA UNII
W4N3HUS9UW
Created by admin on Fri Dec 15 15:41:53 UTC 2023 , Edited by admin on Fri Dec 15 15:41:53 UTC 2023
PRIMARY
CAS
183507-63-3
Created by admin on Fri Dec 15 15:41:53 UTC 2023 , Edited by admin on Fri Dec 15 15:41:53 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE